MedOncNORD AB · Stockholm

Oncology intelligence, from early clinical development to patient care.

MedOncNORD develops ONCOTrack for structured monitoring of treatment-related toxicity and provides independent oncology development intelligence for early clinical programmes.

Explore ONCOTrack Development Intelligence

What we do

Clinical MonitoringONCOTrack

Treatment-aware toxicity monitoring between systemic therapy cycles.

Functional synthetic-data MVP · clinical pilot preparation in Sweden

Development IntelligenceIndependent analysis for early oncology development decisions.

Signal Resilience · Combination Development · CTCAE v6 Readiness

One focus: stronger decisions around treatment effect and toxicity.

Clinical monitoring

ONCOTrack

ONCOTrack is being developed for structured monitoring of treatment-related toxicity between systemic treatment cycles. It is designed to reflect treatment context and the patient’s course across cycles, creating a longitudinal view of what happens between oncology visits.

Functional synthetic-data MVP

Treatment-aware monitoring

EU MDR pathwayClinical pilot preparation

About ONCOTrack

For clinical partners

Shape the first clinical pilot

Oncology teams interested in evaluating structured toxicity monitoring in clinical workflow.

Discuss a pilot →

For investors

ONCOTrack development

A product, regulatory and pilot roadmap is available for qualified discussions.

Request information →

Development Intelligence

Oncology development intelligence for decisions that deserve scrutiny.

For oncology biotech teams, investors and development partners. Each solution addresses a defined development question using explicit methods, stated uncertainty and decision-focused outputs.

Signal Resilience

Design-partner projects

Robustness of an early-phase efficacy signal

Systematic sensitivity analysis of one pre-specified signal across plausible analytical assumptions, showing which conclusions hold and which depend on specific choices.

Signal Resilience →

Combination Development Pilot projects

Benefit-risk patterns in combination regimens

Integrated analysis of dose, available exposure data, efficacy and toxicity across early combination cohorts, describing the observed benefit-risk profile and the questions that remain open.

Combination Development →

CTCAE v6 Readiness

Available

Transition from CTCAE v5.0 to v6.0

Impact assessment of terminology, grading and mapping changes on eCRFs, EDC configuration and safety workflows, before implementation in new study builds or updated templates.

CTCAE v6 Readiness →

ILLUSTRATIVE ANALYSIS · SYNTHETIC DATA · FICTIONAL SPONSOR

Signal Resilience · SR-0001

Robustness assessment of a biomarker-defined response signal.

At the reported 10% cut-off, all 48 specifications had a positive ORR point estimate. Across all cut-offs, 141 of 192 did. The magnitude underpinning the enrichment rationale was not supported.

Explore SR-0001

Original signal

+20 pp

Reported

Confirmed responses only

+7 pp

Collapses

5% / 15% cut-offs

+1 pp / +3 pp

Collapses

20% cut-off

+21 pp

Uninformative · n=6

Exploratory Firth adjustment

+17 pp

Persists

Specifications with 95% CIs entirely above zero

11 / 192

5.7%

VerdictFRAGILE

About our work

Scientific foundation

Our work sits where tumour biology, clinical development and quantitative analysis meet. We work only in oncology.

Wiem Chaabane, PhD

Founder & CEO

Molecular oncology researcher with more than 15 years of experience in cancer research, including five years at Karolinska Institutet.

Pre-specificationStress-test specifications and decision criteria are documented before sensitivity-analysis results are examined.
Standard clinical definitionsRECIST 1.1 for response, CTCAE for toxicity, ICH E9(R1) for estimands and sensitivity analysis.
ReproducibilityVersioned code and data snapshots; every reported figure can be regenerated.
Reported uncertaintyWhere decision-relevant, estimates are presented with uncertainty intervals and stated limitations.
Data protectionNDA and, where applicable, a data processing agreement, with data handling in line with the GDPR.